CBD/THC for Chemotherapy Neuropathy: Why the Primary and Secondary Analyses Matter
A randomized trial did not find a between-group benefit in its primary analysis of chemotherapy-induced peripheral neuropathy; a secondary analysis suggested improvement in sensory symptoms. Reporting only the favorable secondary result would overstate the evidence.
Who was studied?
Weiss and colleagues conducted a 12-week double-blind, placebo-controlled human trial of oral CBD/THC gelcaps in patients with neuropathy after chemotherapy. Forty-six participants were randomized, below the planned target of 100, and 43 completed treatment. This was a clinical symptom study, not an impairment or driving trial.
Preserve the outcome hierarchy
The primary analysis did not show differences between active treatment and placebo. A secondary analysis favored the active group on a sensory-impairment measure. Some neurological examination findings approached statistical significance, while other outcomes, including pain, did not show a treatment effect.
Sensory impairment and pain are related but different endpoints. Improvement on a numbness-related scale cannot automatically be described as demonstrated pain relief, nerve regeneration, or recovery of all function.
What the smaller sample means
Lower enrollment reduces precision and can make a trial less able to detect an effect. It does not establish that the null result was caused by insufficient sample size or that a larger trial necessarily would be positive. Secondary findings require confirmation, particularly when numerous outcomes are examined.
The subsequent open-label observational phase also lacked the same randomized placebo comparison. Its results should not be merged with the blinded phase as equivalent evidence.
Safety and individual application
The trial found no between-group difference in side effects, but a relatively small, selected, short-duration study cannot exclude uncommon or delayed harms. It also does not establish that symptom improvement guarantees normal attention, reaction time, or safe driving.
An accurate discussion identifies the formulation, population, treatment duration, outcome hierarchy, and uncertainty. The study supports further investigation of a possible sensory benefit; it does not establish CBD/THC as a proven cure for chemotherapy neuropathy or determine the cause of an individual patient’s symptoms.
For related context, see our discussion of interpreting THC blood concentrations.
Primary research
Marisa Weiss; Muath Giaddui; Stephanie Kjelstrom; Joseph Gary; Sara Jane Ward; Jessica Burrell; Katherine Diguilio; Gabrielle Bidas; Ebuwa Erebor; Sam Meske; Lisa Saeed; Sarah Windawi; Katherine Aliano Ruiz; Arezoo Ghaneie; Julianne Hibbs; John Marks; David Holtz; Zonera Ali; Aarthi Shevade; Jennifer Sabol; Robin Ciocca; Eric Zeger; Paul Gilman; Sharon Larson; Shoichi Shimamoto; Diana Martinez. Combination CBD/THC in the management of chemotherapy-induced peripheral neuropathy: a randomized double blind controlled trial. Frontiers in Oncology (2025). DOI: 10.3389/fonc.2025.1590168.
